東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Cancer drug safety and public health...

Bennett, Charles.

Linked to FindBook

Google Book

Amazon

博客來

Cancer drug safety and public health policy = a changing landscape /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Cancer drug safety and public health policy/ edited by Charles Bennett, Courtney Lubaczewski, Bartlett Witherspoon.
Reminder of title:	a changing landscape /
other author:	Bennett, Charles.
Published:	Cham :Springer International Publishing : : 2022.,
Description:	xi, 167 p. :ill., digital ;24 cm.
[NT 15003449]:	Fluoroquinolone-Associated Disability and Other Fluoroquinolone Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years -- Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions -- Policing of Drug Safety Information under the False Claims Act -- Translating Research Into Health Policy: The Citizen Petition Experience with the Food and Drug Administration -- Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions -- Was there Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occuring in Copenhagen -- Rituximab-associated Progressive Multifocal Leukoencephalopathy: A fatal adverse drug reaction -- Maximum Accuracy Machine Learning Statistical Analysis - A Novel Approach -- Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at Work -- Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR) -- Moderna, Pfizer-BioNTech, and Johnson & Johnson/Janssen Post-Covid Vaccine Hematological Adverse Events Including Cerebral Venous Sinus Thrombosis (CVST), Thrombotic Thrombocytopenia (VITT), Blood Clots, Increased Vaginal/Menstrual Bleeding and/or Miscarriage, Stillbirth Delivery, or Premature Birth -- Investigating Novel Genetic Fluoroquinolone Associated Disorders.
Contained By:	Springer Nature eBook
Subject:	Antineoplastic agents - Safety measures. -
Online resource:	https://doi.org/10.1007/978-3-031-04402-1
ISBN:	9783031044021

Cancer drug safety and public health policy = a changing landscape /
Cancer drug safety and public health policya changing landscape /[electronic resource] :edited by Charles Bennett, Courtney Lubaczewski, Bartlett Witherspoon. - Cham :Springer International Publishing :2022. - xi, 167 p. :ill., digital ;24 cm. - Cancer treatment and research,v. 1842509-8497 ;. - Cancer treatment and research ;v. 184..

Fluoroquinolone-Associated Disability and Other Fluoroquinolone Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years -- Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions -- Policing of Drug Safety Information under the False Claims Act -- Translating Research Into Health Policy: The Citizen Petition Experience with the Food and Drug Administration -- Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions -- Was there Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occuring in Copenhagen -- Rituximab-associated Progressive Multifocal Leukoencephalopathy: A fatal adverse drug reaction -- Maximum Accuracy Machine Learning Statistical Analysis - A Novel Approach -- Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at Work -- Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR) -- Moderna, Pfizer-BioNTech, and Johnson & Johnson/Janssen Post-Covid Vaccine Hematological Adverse Events Including Cerebral Venous Sinus Thrombosis (CVST), Thrombotic Thrombocytopenia (VITT), Blood Clots, Increased Vaginal/Menstrual Bleeding and/or Miscarriage, Stillbirth Delivery, or Premature Birth -- Investigating Novel Genetic Fluoroquinolone Associated Disorders.

This book offers a wide-ranging description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. The book opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs) A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention - these fines are playing an important role in changing the landscape for pharmaceutical safety.

ISBN: 9783031044021

Standard No.: 10.1007/978-3-031-04402-1doiSubjects--Topical Terms:

3609436
Antineoplastic agents
--Safety measures.

LC Class. No.: RC271.C5

Dewey Class. No.: 615.10289

Cancer drug safety and public health policy = a changing landscape /
LDR:03751nmm a2200337 a 4500 001 2305908
003 DE-He213
005 20221130100738.0
006 m d
007 cr nn 008maaau
008 230409s2022 sz s 0 eng d
020 $a 9783031044021 $q (electronic bk.)
020 $a 9783031044014 $q (paper)
024 7 $a 10.1007/978-3-031-04402-1 $2 doi
035 $a 978-3-031-04402-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.C5
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 615.10289 $2 23
090 $a RC271.C5 $b C215 2022
245 0 0 $a Cancer drug safety and public health policy $h [electronic resource] : $b a changing landscape / $c edited by Charles Bennett, Courtney Lubaczewski, Bartlett Witherspoon.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a xi, 167 p. : $b ill., digital ; $c 24 cm.
490 1 $a Cancer treatment and research, $x 2509-8497 ; $v v. 184
505 0 $a Fluoroquinolone-Associated Disability and Other Fluoroquinolone Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years -- Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions -- Policing of Drug Safety Information under the False Claims Act -- Translating Research Into Health Policy: The Citizen Petition Experience with the Food and Drug Administration -- Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions -- Was there Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occuring in Copenhagen -- Rituximab-associated Progressive Multifocal Leukoencephalopathy: A fatal adverse drug reaction -- Maximum Accuracy Machine Learning Statistical Analysis - A Novel Approach -- Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at Work -- Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR) -- Moderna, Pfizer-BioNTech, and Johnson & Johnson/Janssen Post-Covid Vaccine Hematological Adverse Events Including Cerebral Venous Sinus Thrombosis (CVST), Thrombotic Thrombocytopenia (VITT), Blood Clots, Increased Vaginal/Menstrual Bleeding and/or Miscarriage, Stillbirth Delivery, or Premature Birth -- Investigating Novel Genetic Fluoroquinolone Associated Disorders.
520 $a This book offers a wide-ranging description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. The book opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs) A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention - these fines are playing an important role in changing the landscape for pharmaceutical safety.
650 0 $a Antineoplastic agents $x Safety measures. $3 3609436
650 0 $a Cancer $x Treatment. $3 618125
650 0 $a Pharmaceutical policy. $3 630828
650 0 $a Medical policy. $3 553737
700 1 $a Bennett, Charles. $3 3609432
700 1 $a Lubaczewski, Courtney. $3 3609433
700 1 $a Witherspoon, Bartlett. $3 3609434
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Cancer treatment and research ; $v v. 184. $3 3609435
856 4 0 $u https://doi.org/10.1007/978-3-031-04402-1
950 $a Medicine (SpringerNature-11650)